Navigation Links
Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain

STAMFORD, Conn, Nov. 20 /PRNewswire/ -- Purdue Pharma L.P. and Mundipharma International Corporation Limited, today announced that they have entered into a global strategic alliance with Infinity Pharmaceuticals, Inc. to advance the research, development, and commercialization of Infinity's discovery and early clinical programs in the areas of oncology and neuropathic pain.

The alliance will focus on supporting Infinity's pipeline of novel, small molecule oncology drug candidates, including IPI-926, a potent inhibitor of the Hedgehog pathway, which is being evaluated in a Phase 1 clinical study in patients with advanced solid tumors. IPI-926 has demonstrated significant anti-tumor activity in a number of preclinical models. Infinity will direct and lead oncology discovery and development efforts on a worldwide basis. Under the terms of the agreements, Infinity will retain United States commercialization rights for all oncology products developed under these programs and will pay Mundipharma a royalty on U.S. sales. Mundipharma has the right to commercialize these products outside of the United States, and will pay a royalty to Infinity on sales outside of the United States.

Under a separate agreement, Purdue's associated company, Purdue Pharmaceutical Products L.P., and Mundipharma will have the worldwide rights to assume development of Infinity's fatty acid amide hydrolase (FAAH) program, an experimental target for the treatment of neuropathic pain, at the conclusion of Phase 1 clinical studies. Infinity's FAAH inhibitor program is in lead optimization and the company expects to select a clinical candidate by early 2009. Purdue and Mundipharma will fund all research and development costs of the program through regulatory approval, and will pay a royalty to Infinity on global net sales of any products commercialized.

"Purdue U.S., Purdue Canada, and Mundipharma companies in Europe and Asia have been expanding their therapeutic scope significantly in recent years," said Jim Dolan, Senior Vice President of Licensing and Business Development for Purdue. "Mundipharma's presence in oncology outside of the U.S. is now well-established, and we expect that the broad alliance with Infinity will give us the opportunity to bring to market a number of innovative, best-in-class treatments for cancer patients. In addition, this alliance will also build upon our core franchise in pain on a global basis, with FAAH, a potentially innovative new product for neuropathic pain."

"Infinity's mission is to discover, develop, and deliver to patients important medicines for the treatment of cancer," said Steve H. Holtzman, chair and chief executive officer of Infinity. "This alliance with Purdue and Mundipharma provides Infinity with the financial resources and independence to continue our productive discovery efforts, to expand our clinical development capabilities, and to build our own organization to commercialize our products in the United States. In a nutshell, we have the opportunity to realize all aspects of our mission in a manner that we believe will create meaningful treatments for patients and meaningful value for our shareholders."

The Purdue/Mundipharma/Napp independent associated companies are privately owned companies and joint ventures covering the world's pharmaceutical markets. The companies have particular expertise in drug delivery systems and these are applied to a range of analgesics, respiratory treatments, and cardiovascular drugs. The companies also have a growing presence in the oncology market, and products in the areas of attention deficit hyperactivity disorder, antiseptics and laxatives.

SOURCE Purdue Pharma L.P.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NIH grant to strengthen IU and Purdue program to educate physician-scientists
2. Purdue lab works to improve conditions at indoor swimming pools
3. Purdue Pharma Selects Systech to Provide Sustainable Infrastructure for Serialization
4. Purdue researchers develop technology to detect cancer by scanning surface veins
5. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
6. Parkland Health & Hospital System Rolls Out Innovations PharmASSIST Technology Platform Across Nine Pharmacy Sites
7. NCPA Encourages Member Pharmacists to Consider Refraining From Selling Tobacco Products
8. Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately
9. Genetic disease treatments and pharmacogenetics: From scientific discovery to medical delivery
10. Kmart Pharmacy Celebrates GoldK Day for Seniors
11. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
Post Your Comments:
(Date:11/29/2015)... , ... November 29, 2015 , ... Effective immediately, every ... In addition starting on Black Friday Target is offering a “Buy One Scrub Set, ... is a rare opportunity to purchase IguanaMed at a discounted price. , ...
(Date:11/28/2015)... ... 2015 , ... Safe storage for contraceptive devices may not always be easy ... Jersey and the other from Bradley Beach, New Jersey, there is an easy solution ... having to replace NuvaRings more often than necessary. As such, it affords peace of ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back ... to choose from, the possibilities are endless. Users have full control over angle of ... Pulse masking effects, users are sure to get heads to turn. , ProPanel: Pulse ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... DUBLIN , Nov. 26, 2015 /PRNewswire/ ... announced the addition of the "2016 ... by Test, Country Volume and Sales Segment ... Emerging Opportunities" report to their offering. ... the addition of the "2016 Global ...
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... --> --> Juntendo University ... contrast weighting of MRI for patients with Multiple Sclerosis ... agreement with SyntheticMR in order to use SyMRI in clinical ... to generate multiple contrast images from a single scan and ... making it possible to both fine tune images and recreate ...
Breaking Medicine Technology: